APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT03997383
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Sponsor
- Registry
-
NCT03997383 -
2019-001458-24
-
- Other papers using this trial's data
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
- Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, Czechia, Denmark, France, Hong Kong SAR China, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Portugal, South Korea, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03997383. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-04 (actual); primary completion 2022-06-20 (actual). Results posted on 2023-10-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
- Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Patisiran
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct03997383- Content hash
5f89025ef6c76d17f05e886f5f9a4484db12015ddb667d5f6ad1dc3e2f06b182